Oral solithromycin: Interim Phase II data

Interim data from 6 NASH patients without cirrhosis in an open-label, U.S. Phase II trial showed that once-daily 200 mg oral solithromycin for 1 week followed by 3 times per week for 12 weeks reduced ...